Skip to main content
SpringerLink
Log in

Olanzapine versus Risperidone

A Prospective Comparison of Clinical and Economic Outcomes in Schizophrenia

  • Original Research Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

Objective: To compare the clinical and economic outcomes associatedwith olanzapine and risperidone treatment for schizophrenia.

Design and setting: An international, multicentre, double-blind, prospective study. To facilitate economic comparisons, our sample was restricted to patients enrolled in US sites. 150 patients with a Diagnostic and Statistical Manual of mental disorders, 4th edition (DSM-IV) diagnosis of schizophrenia, schizoaffective disorder or schizophreniform disorder were randomised to therapy with either olanzapine 10 to 20 mg/day (n = 75) or risperidone 4 to 12 mg/day (n = 75) for a maximum of 28 weeks. In addition to tolerability and efficacy assessments, use of health services was assessed at baseline and prospectively, at 8-week intervals and at study completion. Clinically important response, defined as a 40% improvement in the Positive and Negative Syndrome Scale total score, maintenance of response and rates of treatment-emergent extrapyramidal symptoms were compared between groups. Direct medical costs were estimated by assigning standardised prices to resource units. Median total, inpatient/outpatient service and medication acquisition costs were compared between treatment groups.

Main outcome measures and results: The mean modal dosages for the olanzapine and risperidone treatment groups were 17.7 ± 3.4 mg/day and 7.9 ± 3.2 mg/day, respectively. Olanzapine-treated patients were more likely to maintain response compared with risperidone-treated patients (p = 0.048). In addition, a smaller proportion of olanzapine-treated patients required anticholinergic therapy compared with risperidone-treated patients (25.3 vs 45.3%; p = 0.016). Total per patient medical costs over the study interval were $US2843 (1997 values) [36%] lower in the olanzapine treatment group than in the risperidone treatment group (p = 0.342).Medication costs were significantly higher for olanzapine-treated patients ($US2513 vs $US1581; p < 0.001), but this difference was offset by a reduction of $US3774 (52%) in inpatient/outpatient service costs for olanzapine-treated patients in comparison with risperidone-treated patients ($US3516 vs $US7291, p = 0.083).Median cost findings were consistent with results observed using other robust measures of central tendency and provide conservative estimates of potential savings that may be obtained from olanzapine therapy.

Conclusions: In this study, olanzapine-treated patients experienced clinical improvements that translated into savings in costs of care for both inpatient and outpatient services. These savings offset the difference in medication acquisition cost between olanzapine and risperidone.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Table II
Table III
Table IV
Table V
Table VI

Similar content being viewed by others

References

  1. Dixon LB, Lehman AF, Levine J. Conventional antipsychotic medications for schizophrenia. Schizophr Bull 1995; 21: 567–77

    Article  PubMed  CAS  Google Scholar 

  2. Kane JM. Schizophrenia. N Engl J Med 1996; 334: 34–41

    Article  PubMed  CAS  Google Scholar 

  3. Baldessarini RJ, Cohen BM, Teicher M. Pharmacologic treatment. In: Levy ST, Ninan PT, editors. Schizophrenia treatment of acute episodes. Washington, DC: American Psychiatric Press, 1990: 61–118

    Google Scholar 

  4. Davis JM, Barter JT, Kane JM. Antipsychotic drugs. In: Kaplan HI, Sadock BJ, editors. Comprehensive textbook of psychiatry. Vol. 5.Vol. 5.Baltimore (MD): Williams & Wilkins, 1989: 1591–1626

    Google Scholar 

  5. Marder SR. Antipsychotic drugs and relapse prevention. Schizophr Res 1999; 35: S87–92

    Article  Google Scholar 

  6. Weiden PJ, Shaw E, Man JJ. Causes of neuroleptic noncompliance. Psychiatr Ann 1986: 571–5

    Google Scholar 

  7. Casey DE. Tardive dyskinesia and atypical antipsychotic drugs. Schizophr Res 1999; 35: S61–6

    Article  Google Scholar 

  8. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789–96

    Article  PubMed  CAS  Google Scholar 

  9. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients [see comments; published erratum appears in J Clin Psychopharmacol 1993 Apr; 13 (2): 149]. J Clin Psychopharmacol 1993; 13: 25–40

    Article  Google Scholar 

  10. Beasley Jr CM, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial [see comments]. Neuropsychopharmacology 1996; 14: 111–23

    Article  PubMed  CAS  Google Scholar 

  11. Tollefson GD, Beasley Jr CM, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997; 154: 457–65

    PubMed  CAS  Google Scholar 

  12. Arvanitis LA, Miller BG. Multiple fixed doses of ‘Seroquel’ (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 1997; 42: 233–46

    Article  PubMed  CAS  Google Scholar 

  13. Hegerty JD, Baldessarini RJ, Tohen M. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry 1994: 1409–16

  14. Keith SJ. Pharmacologic advances in the treatment of schizophrenia [editorial; comment]. N Engl J Med 1997; 337: 851–2

    Article  PubMed  CAS  Google Scholar 

  15. Lehman A. Evaluating outcomes of treatments fro persons with psychotic disorders. J Clin Psychiatry 1996; 57: S61–7

    PubMed  Google Scholar 

  16. Borison RL. Recent advances in the pharmacotherapy of schizophrenia. Harv Rev Psychiatry 1997; 4: 255–71

    Article  PubMed  CAS  Google Scholar 

  17. Revicki DA. Methods of pharmacoeconomic evaluation of psychopharmacologic therapies for patients with schizophrenia. J Psychiatry Neurosci 1997; 22: 256–66

    PubMed  CAS  Google Scholar 

  18. Revicki DA. Pharmacoeconomic evaluation of treatments for refractory schizophrenia: clozapine-related studies. J Clin Psychiatry 1999; 60: 7–11; discussion 28–30

    Article  PubMed  Google Scholar 

  19. Hamilton SH, Revicki DA, Edgell ET, et al. Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial. Pharmacoeconomics 1999; 15: 469–80

    Article  PubMed  CAS  Google Scholar 

  20. Palmer CS, Revicki DA, Genduso LA, et al. A cost-effectiveness clinical decision analysis model for schizophrenia. Am J Manage Care 1998; 4: 345–55

    CAS  Google Scholar 

  21. Sacristan JA, Gomez JC, Salvador-Carulla L. Cost effectiveness analysis of olanzapine versus haloperidol in the treatment of schizophrenia++ in Spain [in Spanish]. Actas Luso Esp Neurol Psiquiatr Cienc A fines 1997; 25 (4): 225–34

    CAS  Google Scholar 

  22. Revicki DA, Luce BR, Weschler JM, et al. Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients [see comments]. Hosp Community Psychiatry 1990; 41: 850–4

    PubMed  CAS  Google Scholar 

  23. Meltzer HY, Cola P, Way L, et al. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia [see comments]. Am J Psychiatry 1993; 150: 1630–8

    PubMed  CAS  Google Scholar 

  24. Davies LM, Drummond MF. Assessment of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom. Br J Psychiatry 1993; 162: 38–42

    Article  PubMed  CAS  Google Scholar 

  25. Frankenburg FR, Zanarini MC, Cole JO, et al. Hospitalization rates among clozapine-treated patients: a prospective cost-benefit analysis. Ann Clin Psychiatry 1992: 247–50

  26. Reid WH, Mason M, Toprac M. Savings in hospital bed-days related to treatment with clozapine. Hosp Community Psychiatry 1994; 45: 261–4

    PubMed  CAS  Google Scholar 

  27. Jonsson D, Walinder J. Cost-effectiveness of clozapine treatment in therapy-refractory schizophrenia. Acta Psychiatr Scand 1995; 92: 199–201

    Article  PubMed  CAS  Google Scholar 

  28. Rosenheck R, Cramer J, XuW, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia [see comments]. N Engl J Med 1997; 337: 809–15

    Article  PubMed  CAS  Google Scholar 

  29. Addington DE, Jones B, Bloom D, et al. Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study. Clin Ther 1993; 15: 917–26

    PubMed  CAS  Google Scholar 

  30. Guest JF, Hart WM, Cookson RF, et al. Pharmacoeconomic evaluation of long term treatment with risperidone for patients with chronic schizophrenia. Br J Med Econ 1996; 10: 59–67

    Google Scholar 

  31. Viale G, Mechling L, Maislin G, et al. Impact of risperidone on the use of mental health care resources. Psychiatr Serv 1997; 48: 1153–9

    PubMed  CAS  Google Scholar 

  32. Oh P, Einarson TR, Iskedjian M, et al. Pharmacoeconomic evaluation in schizophrenia: clozapine in treatment-resistant schizophrenia and risperidone in chronic schizophrenia. Ottawa (ON): Canadian Coordinating Office for Health Technology Assessment (CCOHTA), 1997 Jul

    Google Scholar 

  33. Albright PS, Livingstone S, Keegan DL, et al. Reduction of health care resource utilization and costs following the use of risperidone for patients with schizophrenia previously treated with standard antipsychotic therapy: retrospective analysis using the Saskatchewan Health Linkable Databases. Clin Drug Invest 1996; 11: 289–99

    Article  Google Scholar 

  34. Keegan DL, Albright P, Petersen T. Long-term healthcare resource utilisation and costs before and after initiation of risperidone treatment in patients with chronic schizophrenia. Clin Drug Invest 1999: 18: 233–7

    Article  Google Scholar 

  35. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997; 17: 407–18

    Article  PubMed  CAS  Google Scholar 

  36. Voris JC, Glazer WM. Use of risperidone and olanzapine in outpatient clinics at six Veterans Affairs hospitals. Psychiatr Serv 1999; 50: 163–4, 168

    Google Scholar 

  37. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994

    Google Scholar 

  38. Gureje O, Lambert T, Grainger D, et al. Australasian Olanzapine Study Group. Olanzapine versus risperidone in the management of schizophrenia: randomized double-blind study in Australia and New Zealand [poster]. 21st Collegium Internationale Neuro Psychopharmacologicum (CINP) Congress: 1998 Jul 12–16; Glasgow

  39. Purdon SE, Jones BD, Stip E, et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for Research in Schizophrenia. Arch Gen Psychiatry 2000; 57 (3): 249–58

    Article  PubMed  CAS  Google Scholar 

  40. Procyshyn RM, Zerjav S. Drug utilization patterns and outcomes associated with in-hospital treatment with risperidone or olanzapine. Clin Ther 1998; 20: 1203–17; discussion 1192–3

    Article  PubMed  CAS  Google Scholar 

  41. Edgell ET, Gregor KJ, Cockburn I. Drug utilization patterns and outcomes associated with in-hospital treatment with risperidone or olanzapine [letter]. Clin Ther 1999; 21: 917–30

    Article  PubMed  CAS  Google Scholar 

  42. Mohr P, Neumann P, Claxton K. A cost-effectiveness clinical decision analysis model for schizophrenia [letter]. Am J Manage Care 1998: 1200–1

    Google Scholar 

  43. Woerner MG, Mannuzza S, Kane JM. Anchoring the BPRS: an aid to improved reliability. Psychopharmacol Bull 1988; 24: 112–7

    PubMed  CAS  Google Scholar 

  44. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) manual. North Tonawanda (NY): Multi-Health Systems, 1986

    Google Scholar 

  45. Guy W, editor. ECDEU assessment manual for psychopharmacology. Publication ADM 76–338. Rockville (MD): US Department of Health, Education, and Welfare, 1976: 76–338

  46. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212: 11–9

    Article  PubMed  CAS  Google Scholar 

  47. Barnes TR. Arating scale for drug-induced akathisia. Br J Psychiatry 1989; 154: 672–6

    Article  PubMed  CAS  Google Scholar 

  48. Guy W. ECDEU assessment manual for psychopharmacology, revised version. Bethesda (MD): U.S. Department of Health, Education and Welfare, 1976: 534–7

    Google Scholar 

  49. Schooler NM, Kane JM. Research diagnosis for tardive dyskinesia [letter]. Arch Gen Psychiatry 1982: 486–7

  50. Finkler S. The distinction between costs and charges. Ann Intern Med 1982: 102–9

  51. Luce BR, Elixhauser A. Estimating costs in the economic evaluation of medical technologies. Int J Technol Assess Health Care 1990; 6: 57–75

    Article  PubMed  CAS  Google Scholar 

  52. Gold MR, Siegel JE, Russell LB, et al., editors. Cost-effectiveness in health and medicine. New York (NY): Oxford University Press, 1996

  53. Payment for part B medical and other health services. Federal register. Washington, DC: HealthCare Financing Administration, 1994: 59: 235

  54. Reed SK, Hennessy KD, Mitchell OS, et al. A mental health capitation program: II. Cost-benefit analysis. Hosp Community Psychiatry 1994; 45: 1097–103

    PubMed  CAS  Google Scholar 

  55. Dwyer DS, Mitchell OS, Cole R, et al. Evaluating mental health capitation treatment: lessons from panel data. Cambridge (MA): National Bureau of Economic Research, 1995

    Google Scholar 

  56. U.S. Bureau of Labor Statistics. CPI detailed report. Washington, DC: Department of Labour, US Bureau of Labor Statistics, 1995 Dec

    Google Scholar 

  57. Palmer CS, Revicki DA, Halpern MT, et al. The cost of suicide and suicide attempts in the United States. Clin Neuropharmacol 1995: S25–33

  58. National Association of Psychiatric Health Systems. Trends in psychiatric health systems 1995 annual survey. Final report. Washington, DC: National Association of Psychiatric Health Systems, 1995

    Google Scholar 

  59. Red book. Pharmacy’s fundamental reference. Monteville (NJ): Medical Economic Data Production Company, 1997

    Google Scholar 

  60. Lee ET. Statistical methods for survival data analysis. 2nd ed. New York (NY): Wiley Interscience, 1992

    Google Scholar 

  61. Koenker R, Bassett G. Regression quantiles. Econometrica 1978; 46: 33–50

    Article  Google Scholar 

  62. Snedecor GW, Cochrane W. Statistical methods. Ames (IA): Iowa State University Press, 1980

    Google Scholar 

  63. Wallace T Ashar V. Sequential methods in model construction. Rev Econ Stat 1972; 54: 172–8

    Article  Google Scholar 

  64. Loosbrock D, Gibson J, Dulisse B, et al. Apples and apples, apples and oranges: the use and abuse of average daily dose in pharmacoeconomic research. Value Health 1999; 2: 227–8

    Article  Google Scholar 

  65. Sacristan JA, Gomez JC, Montejo A-L, et al. Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiological study. Clin Ther 2000; 22: 583–99

    Article  PubMed  CAS  Google Scholar 

  66. SAS Institute Inc. SAS/STAT user’s guide. Version 6. 4th ed. Vols 1 – 2. Cary (NC): SAS Institute, Inc., 1990

    Google Scholar 

  67. Stata Corporation. Intercooled Stata 6.0 for Windows 98/95/NT. College Station (TX): Stata Corporation, 1999

    Google Scholar 

  68. Addington D, Addington J. Costs of novel antipsychotics in clinical practice [poster]. 151st Annual American Psychiatric Association; 1998 May 30–Jun 06; Toronto

  69. Chan Y, Votolato NA, Nasrallah HA. Pharmacoeconomic comparisons of risperidone and olanzapine during acute treatment of schizophrenia [poster]. 151stAnnualAmerican Psychiatric Association; 1998 May 30–Jun 06, Toronto

  70. Love RC, Conley RR, Kelly DL. A dose-outcome analysis of risperidone use in the Maryland State Mental Health System [poster]., 151st Annual American Psychiatric Association; 1998 May 30–Jun 06, Toronto

  71. Bille A, Andersen J. Risperidone Olanzapine Outcomes in Schizophrenia (RODOS): single-center report from an international study series [poster]. 11thWorld Psychiatric Congress; 1999 Aug 6–11, Hamburg

  72. Kasper S, Duchesne I. Risperidone Olanzapine Outcomes in Schizophrenia (RODOS): studies in schizophrenia-combined results [poster]. 11th World Psychiatric Congress; 1999 Aug 6–11; Hamburg

  73. Hargreaves WA, Shumway M. Pharmacoeconomics of antipsychotic drug therapy. J Clin Psychiatry 1996; 57: 66–76

    PubMed  Google Scholar 

  74. Drummond MF, Stoddard GL. Economic analysis and clinical trials. Control Clin Trials 1984: 115–28

  75. Revicki DA. Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia. Schizophr Res 1999; 35: S101–9

    Article  Google Scholar 

  76. LeCompte D, Cookson RF. The economic value of atypical antipsychotics: a comparison of risperidone and olanzapine revisited. Int J Psychiatry Clin Pract 1999: 3: 3–9

    Article  Google Scholar 

  77. Schooler NR. Comments on article by Tran and colleagues: “Double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders” [letter]. J Clin Psychopharmacol 1998; 18 (2): 174–6

    Article  PubMed  Google Scholar 

  78. Gheuens J, Grebb JA. Comments on article by Tran and associates: “Double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders” [letter]. J Clin Psychopharmacology 1998: 18 (2): 176–7

    Article  CAS  Google Scholar 

  79. Kasper S, Kufferle B. Comments on “Double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders” by Tran and Associates [letter]. J Clin Psychopharmacol 1998; 18 (4): 353–6

    Article  PubMed  CAS  Google Scholar 

  80. Risperdal US package insert [online]. Titusville (NJ): Janssen Pharmaceutica, 1999. Available from: URL: http://us.janssen.com/products/pi_files/risperd.pdf [Accessed 2000 Oct 12]

  81. Tollefson GD, Tran PV. Response to comments on Article by Tran and Associates, “Double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders” [letter]. J Clin Psychopharmacol 1998: 18 (2) 177–79

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This study was funded and conducted by Eli Lilly and Company, Indianapolis, Indiana, USA.

Author information

Authors and Affiliations

  1. Health Outcomes Research Scientist, European Health Outcomes Research, Eli Lilly and Company Ltd, Lilly Research Centre, Erl Wood Manor, Windlesham, Surrey, Indianapolis, GU20 6PHUK, Indiana, USA

    Eric T. Edgell (PharmD, MS, Health Outcomes Research Scientist), Scott W. Andersen, Bryan M. Johnstone, Brian Dulisse & Alan Breier

  2. MEDTAP International, Bethesda, Maryland, USA

    Dennis Revicki

Authors
  1. Eric T. Edgell
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Scott W. Andersen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bryan M. Johnstone
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Brian Dulisse
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dennis Revicki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Alan Breier
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Edgell, E.T., Andersen, S.W., Johnstone, B.M. et al. Olanzapine versus Risperidone. Pharmacoeconomics 18, 567–579 (2000). https://doi.org/10.2165/00019053-200018060-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200018060-00004

Keywords

Search

Navigation